Gramm Pharmaceuticals

Gramm Pharmaceuticals is a private specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders. Founded by the Evenstad family following the sale of Upsher-Smith Laboratories, the company operates as a holding entity for several life science interests, most notably its subsidiary Proximagen. Gramm's portfolio historically included the development of Nayzilam (midazolam nasal spray), which was successfully divested to UCB in 2018. Currently, the company leverages its expertise in CNS and drug delivery to advance a pipeline of small molecule candidates targeting conditions such as Parkinson's disease and chronic pain. Headquartered in Morristown, New Jersey, Gramm Pharmaceuticals continues to seek strategic partnerships and acquisition opportunities within the neurology and specialty pharma sectors.